12/10/2019 8:34:33 AM
FDA Grants VistaGen Therapeutics Fast Track Designation For PH94B For Treatment Of Social Anxiety Disorder
11/14/2019 7:33:24 AM
VistaGen Announces Disappointng Topline Phase 2 Results For AV-101
11/7/2019 6:44:13 AM
VistaGen Therapeutics Q2 Net Loss Attributable To Common Stockholders Narrows To $5.7 Mln From $7.7 Mln Last Year
10/28/2019 8:35:25 AM
VistaGen Therapeutics Expands European Patent Protection For AV-101 For Treatment Of Depression And Dyskinesia
10/8/2019 8:35:01 AM
VistaGen Announces Last Patient Completes Dosing In ELEVATE Phase 2 Study Of AV-101 For Major Depressive Disorder
2/13/2019 8:40:49 AM
VistaGen Therapeutics Receives Notice Of Allowance For U.S. Patent For Treatment Of Depression With PH10
10/25/2018 9:20:50 AM
VistaGen Therapeutics Acquires Worldwide Rights To Develop And Commercialize PH10
10/3/2018 8:34:43 AM
VistaGen Receives FDA Fast Track Designation For Development Of AV-101 As Non-Opioid Treatment For Neuropathic Pain
9/13/2018 8:36:26 AM
VistaGen Therapeutics Buys Worldwide License Of Phase 3-Ready CNS Drug Candidate From Pherin
8/14/2018 4:50:49 PM
VistaGen Therapeutics Q1 Loss/share $0.20 Vs. Loss $0.28 Year Ago
8/13/2018 8:35:41 AM
VistaGen, Baylor College Of Medicine To Test VistaGen’s AV-101 For Potential Anti-Suicidal Effects In Veterans
6/26/2018 5:23:49 PM
VistaGen Therapeutics FY18 Loss/share $1.12 Vs. Loss $1.54 Year Ago
6/11/2018 8:41:37 AM
VistaGen Therapeutics Receives Notice Of Allowance For Japanese Patent For Use Of Stem Cells
5/23/2018 8:37:26 AM
VistaGen Therapeutics Receives Notice Of Allowance Of U.S. Patent For Treatment Of Osteoarthritis And Joint Injuries
5/2/2018 8:35:50 AM
VistaGen Receives Notice Of Allowance For Japanese Patent Regarding Methods Of Production For AV-101
4/10/2018 8:32:50 AM
VistaGen Receives European Patent Regarding Methods Of Production For AV-101